Skip to main content

Table 2 Prevalence of FibroTest with high-risk profile of false positive/negative (RFPN1)

From: Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

Parameters

All (P3) n = 345,695

Reference center (P4) n = 24,872

 

Lower limit and

RFPN n (%)

Upper limit and

RFPN n (%)

Lower limit and

RFPN n (%)

Upper limit and

RFPN n (%)

Haptoglobin g/L

1590 (0.46%)3

0 (0%)2

324 (1.30%)

0 (0%)

Apolipoprotein A1 g/L

118 (0.03%)3

732 (0.21%)2

25 (0.10%)

57 (0.23%)

Alpha-2 macroglobulin g/L

419 (0.12%)2

427 (0.12%)3

54 (0.22%)

24 (0.10%)

GGT IU/L

0 (0%)

78 (0.02%)3

0 (0%)

8 (0.03%)

Total Bilirubin, μmol/L

0 (0%)

6 (0.001%)3

0 (0%)

0 (0%)

  1. 1Defined as a change > 0.30 in Fibrotest (at least 1.5 fibrosis METAVIR stage) when switching to the median value of the given parameter. Overall at least one parameter out of limits with significant impact was observed in 3349 cases (0.97%).
  2. 2 Risk of false negative
  3. 3 Risk of false positive